Summary of the Conference Call for Jingfeng Medical Industry Overview - The rise of high-end medical manufacturing in China is driving the development of domestic surgical robots, with companies like Jingfeng Medical showcasing differentiated advantages in remote and single-port surgical robots, particularly in developing countries where there is significant unmet clinical demand [2][3] Company Performance - Jingfeng Medical is recognized as a benchmark enterprise in the domestic laparoscopic surgical robot market, holding approximately 20% market share, second only to the Da Vinci system [4] - The company is expected to achieve significant overseas success, with installation and shipment volumes nearing 50 units by 2025, and rapid growth anticipated in 2026 [5] Financial Projections - Revenue forecasts for Jingfeng Medical are projected at 432 million yuan, 811 million yuan, and 1.232 billion yuan for the years 2025, 2026, and 2027 respectively [6] - A target price of 773.2 yuan or 79.57 HKD is set based on a 35x price-to-sales ratio for 2026, with an initial rating of "buy" [6] Core Technologies and Products - Jingfeng Medical is the first in China and the second globally to receive certifications for multi-port, single-port, and natural orifice surgical robots [7] - The flagship product, MSP2000, is the world's first integrated single-multi-port robotic surgical system, which received the C1 certification in October 2025 [7] Commercialization Progress - Since the commercialization of the multi-port laparoscopic surgical robot at the end of 2022, Jingfeng Medical has ranked first in domestic sales, covering over 220 hospitals across more than 30 provinces [8] - The company has signed sales agreements for 118 core products by the end of 2025, with 72 units destined for international markets, indicating a scaling global presence [8] Innovative Solutions - The company has launched a tri-modal surgical solution that integrates multi-port, single-port, and remote capabilities, reducing hospital acquisition costs and enhancing operational efficiency [9] - Its adaptability covers various laparoscopic surgical scenarios, including urology and gynecology, facilitated by high-precision control systems and low-latency remote systems [9] Management and R&D Strength - Founded by experienced professionals, Jingfeng Medical has a cross-disciplinary R&D team of 265 members, holding 453 authorized patents and 213 pending applications, ranking first among domestic peers [10] - The management team has extensive backgrounds in leading medical and precision instrument companies, providing a solid foundation for rapid growth [10] Future Development Prospects - With increasing installation volumes and enhanced product performance, the company is expected to achieve profitability by 2026, maintaining stable gross margins while expanding market penetration [11] - Continuous investment in R&D and marketing is anticipated to solidify its industry-leading position and drive further breakthroughs [11] Advantages of Robotic Surgery - Robotic surgical systems offer significant advantages over traditional laparoscopic surgery, including reduced impact from human factors like fatigue and emotion, and a wide range of applications across various medical fields [12] Market Comparison - The global laparoscopic surgical robot market is rapidly expanding, with projections indicating substantial growth in both installation volumes and market size through 2033 [16] - In China, the market is expected to grow significantly, with installation numbers projected to rise from 134 units in 2019 to 511 units by 2024, reflecting a compound annual growth rate of approximately 30% [20] Competitive Landscape - In China, 13 multi-port laparoscopic surgical robots have received regulatory approval, with 11 being domestic brands, showcasing a competitive local market [21] - Jingfeng Medical's products are noted for their affordability and advanced technology, allowing for widespread application in various hospital settings [21] International Expansion - Jingfeng Medical has established a robust commercialization team and has made significant strides in international markets, including obtaining CE certification in Europe and expanding into Southeast Asia [22][23] Conclusion - Jingfeng Medical is positioned for substantial growth in the surgical robot market, with innovative products, strong financial projections, and a commitment to expanding both domestic and international presence [24]

（来源：黑龙江日报） 转自：黑龙江日报 □本报记者 彭溢 近日，哈尔滨思哲睿智能医疗设备股份有限公司（以下简称思哲睿）迎来了具有里程碑意义的时刻—— 其独立研发、具备自主知识产权的康多机器人胸腹腔内窥镜手术系统，顺利通过了国际权威检测与认证 机构CSA集团颁发的CB证书，成为中国首个取得该证书的国产腔镜手术机器人系统。CB证书受国际电 工委员会50余个成员国广泛认可，是产品进入国际市场的"通行证"，这为中国国产手术机器人走向世界 舞台奠定了坚实基础。这一成果的背后，是思哲睿团队十余年深耕不辍的创新积淀与矢志不渝的初心坚 守。 破局：从实验室到市场的跨越 "腔镜手术机器人是各类机器人中系统最复杂、研发难度最大的。"机器人领域资深专家、哈尔滨工业大 学教授杜志江坦言。作为技术负责人，他携手北京301医院与多所高校，承担国家863计划重点项目，聚 焦医生控制台、机械臂等核心模块研究。2011年，国内第一台可全流程完成动物实验的腔镜手术机器人 问世，2013年课题通过验收。但实验室的成功只是起点，从实验数据到临床可用，从技术原型到合规产 品还有无数难关待破。 彼时，腔镜手术机器人市场被国外品牌独家垄断，单台高昂的售价 ...